IMR Press / EJGO / Volume 24 / Issue 2 / pii/2003147

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Radiochemotherapy for patients with locally advanced cervical cancer: early results

Show Less
1 Ege University Faculty of Medicine, Department of Radiation Oncology, Izmir, Turkey
2 Manisa State Hospital, Manisa, Turkey
3 Ege University Faculty of Medicine, Department of Gynecologic Oncology, Izmir, Turkey
4 Tepecik S. S. K. Hospital, Department of Gynecologic Oncology, Izmir, Turkey
Eur. J. Gynaecol. Oncol. 2003, 24(2), 191–194;
Published: 10 April 2003

Purpose: Radiotherapy is the standard treatment for locally advanced cervical cancer. Recent results of the prospective randomized trials have shown an overall survival and local control advantage for cisplatin-based therapy given concurrently with radiation therapy. Thirty-nine patients who received concurrent chemoradiation between October 1999 and December 2000 were evaluated for treatment response, local control and toxicity. Materials and methods: Thirty-nine patients with Stage IB through IVA cervical carcinoma received weekly cisplatin (40 mg/m2) concurrent with radiotherapy. Thirty-two patients received both external and intracavitary radiotherapy and seven patients received only external radiotherapy because of insufficient tumor response for intracavitary application. Total external radiotherapy dose was 64.8 Gy with 1.8 Gy daily fractions in patients who received only external radiotherapy. Midline shielding was performed at 50.4 Gy in patients who were going to receive brachytherapy and the total external radiotherapy dose was 54-59.4 Gy. Brachytherapy was performed with a Rotterdam applicator via the microSelectron HDR machine. A total dose of 8.5-18 Gy was applied to point A. Results: Median age was 55. Distribution by stages were as follows: Stage IB 5.1 %, IIA 28.2%, IIB 43.6%, IIIA 7.7%, IIIB 12.8% and IVA 2.6%. Histologically 33 (84.6%) were epidermoid carcinoma, one was adenocarcinoma, two were undifferentiated carci­noma, one was malignant epithelial tumor. In two patients histological type could not be specified. The median duration of follow­up was 20 months. Four patients had local recurrence and three developed distant metastases. Thirty patients (76.9%) had complete response, eight had (20.5%) partial response and one had (2.6%) stable disease. During or after radiochemotherapy 46.2% of the patients developed toxicity due to chemotherapy. Early and late radiation morbidity rates were 66.7% and 71.8%, respectively. No grade III-IV toxicity was observed. Conclusion: Concurrent chemoradiation for locally advanced cervical cancer is the treatment of choice in suitable patients providing high response rates with acceptable toxicity.

Cervical cancer
Back to top